Israeli life science innovation on show at prestigious Swiss forum

The conference will bring together leading Israeli companies in the fields of medtech, biotech, pharmaceuticals, diagnostics and digital health.

February 17, 2019 15:09
2 minute read.
Digital Health [Illustrative]

Digital Health [Illustrative]. (photo credit: ING IMAGE/ASAP)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Dozens of Israeli life-sciences start-ups will showcase their innovative wares to investors and corporate leaders next week at Sachs Associates’ Annual European Life Sciences CEO Forum in Zurich, Switzerland.
The influential forum will host the inaugural GoforIsrael Life Sciences Conference on February 26. It aims to establish strategic alliances between Israeli innovators and partners in Europe, as well as address issues related to raising capital.
Organized by Tel Aviv-headquartered Cukierman & Co. Life Sciences and Sachs Associates, the conference will bring together leading Israeli companies in the fields of medtech, biotech, pharmaceuticals, diagnostics and digital health.
The event is Cukierman’s twenty-first Israel-related business conference. It is supported by the Economy Ministry, the Israel Innovation Authority and Israeli Ambassador to Switzerland and Liechtenstein Jacob Keidar.
“We chose this time to dedicate the GoforIsrael Conference to life sciences only, in response to growing demand for Israeli technologies on behalf of investors, corporations and life sciences companies in Europe,” said Dr. Laurent Choppe, managing partner of Cukierman & Co.

Dr. Laurent Choppe, Managing Partner of Cukierman & Co Life Sciences. (Credit: Dror Sithakol)

Among the 30 start-ups due to present their innovations at the conference are vital-sign monitoring technology company Neteera, cancerous tissue characterization technology firm Dune Medical, scientific dietary supplements developer Nutritional Growth Solutions, and epigenetics cancer detection company Nucleix.
“The life sciences field was one of the fastest growing in 2018 in terms of fund raising, investing and exiting Israeli start-ups, and we expect this trend to continue this year,” said Choppe.
“The Sachs Forum gives Israeli entrepreneurs an excellent opportunity to meet with leading investors in the field in a focused and unmediated manner under one roof.”
Check Point Software co-founder and aMoon Fund anchor investor Marius Nacht, Israel Innovation Authority chairman Dr. Ami Appelbaum, and Rainbow Medical founder and CEO Efi Cohen-Arazi are among many Israeli healthcare technology leaders due to address the conference.
Last year, GoforIsrael was hosted in Foshan, China, and attracted more than 100 Israeli companies, 500 investors, 1,200 participants and led to more than 800 one-on-one meetings.
In recent years, advancing digital health has been a key focus of both Israeli start-ups and the government, boosted by the country’s strategic advantage in almost-universal healthcare data.
In March 2018, the government approved a one-billion shekel ($300 million) five-year national digital health plan that includes technological development, international cooperation, concentrated academic and industrial efforts and regulatory changes, in order to encourage data research.
Today, Israel’s biopharma industry numbers some 200 companies, with approximately 15 new companies established every year. In 2018, pharma start-ups raised a record $1.2 billion in 126 deals. Medical devices companies were the beneficiaries of approximately half of the funding.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

July 21, 2019
Israel beats Spain to win the Under-20 basketball title


Cookie Settings